CN1093714A - Lentinan - Google Patents
Lentinan Download PDFInfo
- Publication number
- CN1093714A CN1093714A CN 93102815 CN93102815A CN1093714A CN 1093714 A CN1093714 A CN 1093714A CN 93102815 CN93102815 CN 93102815 CN 93102815 A CN93102815 A CN 93102815A CN 1093714 A CN1093714 A CN 1093714A
- Authority
- CN
- China
- Prior art keywords
- lentinan
- seminose
- lactosi
- glucose
- semi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of structural formula is main chain with β (1-3), and β (1-6) is branched lentinan, and it is obtained after by artificial separation massee fruiting bodies.Its molecular-weight average is 55～1,100,000, and contained each component and content thereof are as follows in the per unit quantity:
Glucose 60.7% semi-lactosi 26.7%
Seminose 11.2% pentose 1.4%
The present invention has following advantage compared to existing technology, and biological activity is strong, the curative effect height.Not only can be used for treating immunodeficiency diseases, but also can be used for treating chronic hepatitis, and side effect is little, occurrence rate only is 0.75%.
Description
The present invention relates to a kind of glucan, particularly a kind of lentinan.It utilizes agaric material fungi one Lentinus Edodes fungus to eat sporophore through the perfume (or spice) of inoculation culture to be raw material, to prepare after artificial the separation.
A kind of lentinan of the once public mistake of Japan, its molecular-weight average is 500,000, finds after clinical application, this lentinan has following several side effect: shock, feel sick, vomit, oligoleukocythemia, hemoglobin reduction, and the narrow sensation of throat is arranged.These side effect occurrence rates are 6.8%.From result of treatment, it can only treat tumor disease, does not have extensive result of treatment.
The objective of the invention is to overcome weak point of the prior art, and provide a kind of side effect little, therapeutic domain is wider, not only can treat tumor disease, also can treat the lentinan of some other disease.
The objective of the invention is to realize by following approach.
Lentinan, structural formula is a main chain with β (1-3), β (1-6) is a branch, obtains behind artificial separation mushroom fruiting body, contains glucose, components such as semi-lactosi and seminose, said lentinan molecular-weight average is 550,000～1,100,000.
According to pertinent data, a large amount of evidences, molecular weight is big more, and then viscosity is big more, and it is senior that molecular structure is tending towards more, and the biological activity of lentinan is just strong more.
But molecular weight is too big, and the medicine side reaction has also strengthened, and is difficult for making.
Experiment and clinical verification show that molecular-weight average is 550,000～1,100,000, can take into account these two factors of biological activity and the former reaction of medicine simultaneously.
Purpose of the present invention can also realize by following approach.
Said lentinan molecular-weight average is preferably 70～900,000.
In the one Board Lot lentinan, contained relevant component and content thereof are as follows:
Glucose 55%～65% semi-lactosi 23%～30%
Seminose 8%～13% pentose 1.0%～2.0%
In the one Board Lot lentinan, contained relevant component and content thereof are as follows:
Glucose 60.7% semi-lactosi 26.7%
Seminose 11.2% pentose 1.4%
Said lentinan purity is at least 92%.
Purity is more than 92%, comprises 92% lentinan and can be used as intravenous injection.
Lentinan of the present invention once carried out clinic trial, and its clinic trial situation and result are as follows:
(1) treatment chronic viral hepatitis 216 examples, total effective rate is 84.3%.Double blind control treatment chronic viral hepatitis 144 examples, total effective rate is 80.5%.The III clinical trial phase of this product, treatment chronic viral hepatitis 108 examples, and through near, the long-term follow-up observation of 6 months and 12 months, satisfactory effect.Total effective rate is respectively 85.2%, 86.9% and 88.2%.Press the Chinese medical discrimination somatotype and judge curative effect, better with empty type of liver depression and qi stagnation and blood stasis type curative effect.Lentinus edodes polysaccharide injecta treatment chronic viral hepatitis efficacy consolidation is described.ALT 1 year normalization rate at a specified future date reaches 82.9%.The treatment of HBeAg, negative conversion rate is to be to be 54.8% after 44.7%, 12 month after 46.7%, 6 month after 2 months, has confirmed that this product has the effect of the hepatitis B virus duplication of inhibition.
(2) during the treatment esophageal carcinoma, carcinoma of gastric cardia and cancer of the stomach totally 71 examples, major part are, late tumor, lesion portion is alleviated and the person's of stablizing 53 examples, total effective rate 74.6%.Press the Chinese medical discrimination somatotype and judge curative effect, the esophageal carcinoma is with QI and phlegm stagnating each other type, the stagnant type of blood stasis phlegm; Cancer of the stomach is better with resistance type person's curative effect in liver-stomach disharmony type, spleen-stomach deficiency-cold and the stasis of blood poison.Be favourable lifetime to the prolongation tumour patient, particularly can adopt the old tumour patient that can not tolerate chemotherapeutics, and can alleviate the toxic side effects of chemotherapy.
In 359 examples of clinical use, side effect 3 examples are arranged, fash 2 examples wherein, 1 example uncomfortable in chest, there is mild pain the individual patient injection site, and the side effect occurrence rate is 0.75%.
In sum, the present invention has following advantage compared to existing technology: few side effects, side effect occurrence rate only are 0.75%.The side effect hazard rating is low; Therapeutic domain is wide, not only can be used for treating kinds of tumors diseases such as the esophageal carcinoma, carcinoma of gastric cardia and cancer of the stomach, and can be used for the treatment of chronic viral hepatitis, and biological activity is strong simultaneously, and result of treatment is good, the total effective rate height.
Below we carry out more detailed description to the present invention in conjunction with the embodiments.
Embodiment:
Lentinan, by obtaining the outward appearance powder that is white in color behind the artificial separation mushroom fruiting body, its molecular-weight average is 900,000, wherein maximum molecular weight is 1,290,000, minimum molecular weight is 70,000, its structural formula is a main chain with β (1-3), and β (1-6) is a branch, and contained each component and content thereof are as follows in the said lentinan:
Glucose 60.7% semi-lactosi 26.7%
Seminose 11.2% pentose 1.4%
Claims (5)
1, lentinan, structural formula is a main chain with β (1-3), β (1-6) is a branch, obtain behind artificial separation mushroom fruiting body, its composition has glucose, components such as semi-lactosi and seminose, it is characterized in that said lentinan molecular-weight average is 55～1,100,000.
2, lentinan according to claim 1 is characterized in that, said lentinan molecular-weight average is 700,000～900,000.
3, lentinan according to claim 2 is characterized in that, in the Board Lot lentinan, contained each component and content thereof are as follows.
Glucose 55%～65% semi-lactosi 23%～30%
Seminose 8%～13% pentose 1.0%～2.0%
4, lentinan according to claim 3 is characterized in that, contained each component of a Board Lot lentinan and content thereof are as follows.
Glucose 60.7% semi-lactosi 26.7%
Seminose 11.2% pentose 1.4%
5, lentinan according to claim 1 is characterized in that, said lentinan purity is at least 92%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93102815 CN1093714A (en) | 1993-03-11 | 1993-03-11 | Lentinan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93102815 CN1093714A (en) | 1993-03-11 | 1993-03-11 | Lentinan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1093714A true CN1093714A (en) | 1994-10-19 |
Family
ID=4984321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93102815 Pending CN1093714A (en) | 1993-03-11 | 1993-03-11 | Lentinan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1093714A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001044263A1 (en) * | 1999-12-16 | 2001-06-21 | Beijing Zhong Ke Zhi Chuang Science & Technology Ltd. | Oligosaccharides, a process for preparation thereof and pharmaceutical combination containing the same compounds |
| CN1330671C (en) * | 2002-10-08 | 2007-08-08 | 株式会社利根 | Chitosan-containing polysaccharide, method for preparing the same and use thereof |
| US20090143280A1 (en) * | 2005-06-15 | 2009-06-04 | Medimush A/S | Anti-cancer combination treatment and kit-of-parts |
| CN102408494A (en) * | 2011-11-30 | 2012-04-11 | 杭州众芝康菇生物技术有限公司 | Grifola frondosa polysaccharide ZZK component and preparation method thereof |
-
1993
- 1993-03-11 CN CN 93102815 patent/CN1093714A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001044263A1 (en) * | 1999-12-16 | 2001-06-21 | Beijing Zhong Ke Zhi Chuang Science & Technology Ltd. | Oligosaccharides, a process for preparation thereof and pharmaceutical combination containing the same compounds |
| CN1330671C (en) * | 2002-10-08 | 2007-08-08 | 株式会社利根 | Chitosan-containing polysaccharide, method for preparing the same and use thereof |
| US20090143280A1 (en) * | 2005-06-15 | 2009-06-04 | Medimush A/S | Anti-cancer combination treatment and kit-of-parts |
| US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
| CN102408494A (en) * | 2011-11-30 | 2012-04-11 | 杭州众芝康菇生物技术有限公司 | Grifola frondosa polysaccharide ZZK component and preparation method thereof |
| CN102408494B (en) * | 2011-11-30 | 2013-11-20 | 杭州众芝康菇生物技术有限公司 | Grifola frondosa polysaccharide ZZK component and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69529213T2 (en) | USE OF MAGNESIUM-CONTAINING COMPOUNDS FOR THE TREATMENT OR PROPHYLAXIS OF CANCER AND AUTOIMMUNE DISEASES | |
| CN104547774A (en) | Traditional Chinese medicine composition for treating liver diseases, and preparation method and applications thereof | |
| CN1093714A (en) | Lentinan | |
| CN1044777C (en) | Analgesic plaster for cancer pain and its preparing method | |
| CN101502607A (en) | Cordyceps sinensis and mushroom composition, Cordyceps sinensis and mushroom polysaccharide oral liquid, and preparation method thereof | |
| CN1114443C (en) | Medicine for induction-differential therapy and its application | |
| CN1108809C (en) | Medicine for treating leukoderma and preparing process thereof | |
| CN1059800C (en) | Injection containing ginseng and astragalus root components | |
| CN1850149A (en) | Compounded preparation of Radix As tragali seu Hedy ari extract and mushroom polysaccharide and preparing method | |
| CN1212129C (en) | Ketangwan pills as diabetes treating medicine capable of inducing insulin synthesis and its prepn. | |
| CN1129448C (en) | Chinese medicine bolus for treating cataract | |
| CN115192684B (en) | A Chinese medicinal composition for relieving or treating pain, and its preparation method | |
| CN1040621C (en) | Medicine for treating leucoderma | |
| CN1095658C (en) | Foot bathing lotion for eliminating tumor | |
| CN1077386A (en) | A kind of Chinese patent medicine for the treatment of angina pectoris | |
| CN1771984B (en) | New use of extracellular polysaccharide of halophilous aphanothece | |
| CN1058882C (en) | Oral liquor for treating tumour and disease of liver, and preparation method thereof | |
| CN1228977A (en) | Ointment for treating cancer and preparation method thereof | |
| CN1093765C (en) | Chaiqi injection for treating viral hepatitis | |
| CN1102407C (en) | Antidepressive capsule and preparing process thereof | |
| CN106540153B (en) | Traditional Chinese medicine composition containing mulberry leaves and application thereof | |
| CN1059835C (en) | Anticancer analgesic plaster and its preparing method | |
| CN112618686A (en) | A Chinese medicinal composition for preventing and treating hypertension, and its preparation method | |
| CN1181830C (en) | Yunnan Heiyao and its application in treating tumors | |
| CN1049149C (en) | Liver cancer-curing oral liquid prepared with white ant as main material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |